What is chelation in nuclear medicine?
Chelation in nuclear medicine is the process by which a radionuclide, typically a metal ion, is bound securely within a specialised chemical structure called a chelator. The chelator forms multiple bonds with the metal ion, stabilising it and preventing it from dissociating in vivo.
Chelation is the chemical binding of a metal radionuclide within a stable molecular structure, ensuring correct biodistribution and in vivo stability.
Chelation is essential for many radiopharmaceuticals, particularly those using metallic radionuclides such as gallium-68, indium-111, or lutetium-177. Without stable chelation, the radionuclide could detach and distribute non-specifically, degrading image quality and increasing radiation dose to non-target tissues.
Understanding the physics
Many medically useful radionuclides are metals that exist as positively charged ions in solution. On their own, these ions would interact non-specifically with proteins, bone, or other tissues.
A chelator is a molecule designed to “wrap around” the metal ion, forming multiple coordinate bonds. This creates a stable complex that holds the radionuclide in place.
The stability of this complex depends on:
The chemical compatibility between the metal ion and the chelator
The strength of the coordinate bonds
The in vivo environment (pH, competing ions)
Chelation must be strong enough to prevent dissociation after injection. If the radionuclide detaches, it may accumulate in unintended organs. For example, free gallium may localise in bone, and free indium may bind to plasma proteins.
In receptor imaging, the chelator is often attached to a targeting molecule (such as a peptide or antibody). The chelator binds the radionuclide, while the targeting molecule directs the compound to specific receptors.
Chelation therefore enables the use of metallic radionuclides in targeted imaging and therapy.
Where this matters clinically
Stable chelation ensures correct biodistribution and reliable imaging. Poor chelation can result in unexpected tracer uptake and increased radiation exposure to non-target organs.
Chelation chemistry is central to modern PET tracers such as Ga-68-labelled peptides and therapeutic agents such as Lu-177 compounds.